If Anavex can improve 10 or 15% of patients, slow decline in 50 or 60%, who wouldn’t drop everything and RUN to get Blarcamesine, to find out if they could be improved?
Are you expecting people to stay on anything that does nothing when there’s something out there that could help?
There were also a lot of subjects that continued to decline albeit at a reduced rate and some that quit declining. Those results aren't going to cause "the existing supply chain" to fall apart.